Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 18/20 | 0.33 |
| ▸ | CDK2 | P24941 | 18/20 | 0.33 |
| ▸ | GSK3B | P49841 | 9/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553916 | 0.91 | EPHX1 (0.40) | CCNE1CDK2GSK3BDPP4 | |
| SCHEMBL22859987 | 0.91 | CYP3A4 (0.32) | CCNE1CDK2DPP4 | |
| SCHEMBL17190389 | 0.90 | CCNE1 (0.33) | CCNE1CDK2GSK3B | |
| SCHEMBL17192565 | 0.90 | CHRM1 (0.32) | — | |
| SCHEMBL20017304 | 0.85 | — | — | |
| SCHEMBL17190440 | 0.85 | MAPT (0.31) | — | |
| SCHEMBL17192566 | 0.84 | — | — | |
| SCHEMBL17190381 | 0.83 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL17190357 | 0.82 | SMN1; SMN2 (0.33) | DPP4 | |
| SCHEMBL17190364 | 0.82 | DPP4 (0.30) | CCNE1CDK2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-10927139-B2 | Chemically cleavable group | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-02-23 | — | — | US | disclosed |
| US-10004810-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | CCNE1 3054/4885CDK2 963/4885GSK3B 239/4885 |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | CCNE1 1396/4885CDK2 1201/4885GSK3B 3770/4885 |
| US-10927139-B2 | Chemically cleavable group | SQLE, CTRL, ENO1 | CCNE1 1396/4885CDK2 1201/4885GSK3B 3770/4885 |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KIT, JMJD7, TPSB2 | CCNE1 1361/4885CDK2 416/4885GSK3B 1797/4885 |
| US-11857636-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | CCNE1 3054/4885CDK2 963/4885GSK3B 239/4885 |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | CCNE1 3054/4885CDK2 963/4885GSK3B 239/4885 |
| US-10004810-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | CCNE1 3054/4885CDK2 963/4885GSK3B 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.